Document Type : Original Research

Authors

1 Pathology Department, Faculty of Medicine, Fayoum University, Faiyum, Egypt

2 Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Abstract

Background & Objective: Colorectal cancer is the third most common cause of cancer death worldwide. Stanniocalcin 2 (STC2) is a glycoprotein hormone over-expressed in many human cancers where it regulates tumor progression and invasion. Evaluating its expression in colorectal cancer and its relation with different clinicopathological parameters can provide valuable information about its role in colorectal cancer progression and behavior.
Methods: This retrospective study was conducted on tissue samples of colorectal cancer. The STC2 immunohistochemical expression was detected and evaluated in 60 cases of colorectal cancer tissue samples of formalin-fixed and paraffin-embedded blocks. Then statistical analysis was performed to assess the relationship between its expression level and several clinicopathological parameters in the studied cases.
Results: Statistically significant associations were found between the high level of STC2 immunohistochemical expression and histological tumor grade (P<0.001), tumor depth of invasion (T stage) (P=0.004), lymph node metastasis (N stage) (P=0.001), tumor Dukes’ stage (P<0.001), the presence of lymphovascular invasion (P<0.001), and perineural invasion (P<0.001).
Conclusion: STC2 over-expression in colorectal cancer may be associated with more aggressive tumor behavior including increased tumor invasion, higher histological grade, higher rate of nodal metastasis and increased incidence of lymphovascular and perineural invasions. These data suggest a potential role for STC2 as a predictive biomarker for tumor behavior in colorectal cancer patients.

Keywords

Main Subjects

  1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. [DOI:10.5114/pg.2018.81072] [PMID] [PMCID]
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. [DOI:10.3322/caac.21551] [PMID]
  4. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J. 2008;84(994):403-411. [DOI:10.1136/jcp.2007.054858]
  5. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017. 6;67(3):177-193. [DOI:10.3322/caac.21395] [PMID]
  6. Joshi AD. New Insights Into Physiological and Pathophysiological Functions of Stanniocalcin 2. Front. Endocrinol 2020;11:172. [DOI:10.3389/fendo.2020.00172] [PMID] [PMCID]
  7. Joshi AD, Carter DE, Harper TA Jr, Elferink CJ. Aryl hydrocarbon receptor-dependent stanniocalcin 2 induction by cinnabarinic acid provides cytoprotection against endoplasmic reticulum and oxidative stress. J Pharmacol Exp Ther. 2015;353(1):201-12. [DOI:10.1124/jpet.114.222265] [PMID]
  8. Zeiger W, Ito D, Swetlik C, Oh-hora M, Villereal ML, Thinakaran G. Stanniocalcin 2 is a negative modulator of store-operated calcium entry. Mol Cell Biol. 2011;31(18):3710-22. [PMID] [PMCID] [DOI:10.1128/MCB.05140-11]
  9. Zhou J, Li Y, Yang L, Wu Y, Zhou Y, Cui Y, Yang G, Hong Y. Stanniocalcin 2 improved osteoblast differentiation via phosphorylation of ERK. Mol Med Rep 2016;14: 5653-5659. [DOI:10.3892/mmr.2016.5951] [PMID]
  10. Jepsen MR, Kløverpris S, Bøtkjær JA, Wissing ML, Andersen CY, Oxvig C. The proteolytic activity of pregnancy-associated plasma protein-A is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development. Hum Reprod. 2016;31(4):866-874. [DOI:10.1093/humrep/dew013] [PMID]
  11. Law AY, Wong CK. Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol. 2013. 15; 374(1-2):73-81. [DOI:10.1016/j.mce.2013.04.024] [PMID]
  12. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML et al. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol. 2004;24(21):9456-69. [DOI:10.1128/MCB.24.21.9456-9469.2004] [PMID] [PMCID]
  13. Kim PH, Na SS, Lee B, Kim JH, Cho JY. Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress. BMB Rep. 2015;48(12):702-707. [PMID] [PMCID] [DOI:10.5483/BMBRep.2015.48.12.158]
  14. Hou J, Wang Z, Xu H, Yang L, Yu X, Yang Z, et al. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS ONE. 2015;10 (4): e0122179. [DOI:10.1371/journal.pone.0122179] [PMID] [PMCID]
  15. Zhang C, Chen S, Ma X, Yang Q, Su F, Shu X et al. Upregulation of STC2 in colorectal cancer and its clinicopathological significance. Onco Targets Ther. 2019,15;(12):1249-1258. [DOI:10.2147/OTT.S191609] [PMID] [PMCID]
  16. Wang Y, Wu J, Xu J, Lin S. Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinoma. Biosci Rep. 2019, 26;39(4): BSR20182057. [DOI:10.1042/BSR20182057] [PMID] [PMCID]
  17. Todd JR, Ryall KA, Vyse S, Wong JP, Natrajan RC, Yuan Y et al. Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget. 2016 Sep 27;7(39):62939-62953. [DOI:10.18632/oncotarget.11307] [PMID] [PMCID]
  18. Zhang ZH, Wu YG, Qin CK, Rong ZH, Su ZX, Xian GZ. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma. Oncol Lett. 2014 Nov;8(5):2160-2164. [DOI:10.3892/ol.2014.2520] [PMID] [PMCID]
  19. Dawson B and Trapp R. Basic and Clinical Biostatistics, 4 th Edition, New York, United States, Mcgraw-Hill Medical Publishing Inc.;2004: P. 23,61,24.
  20. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol.vol. 2014, Article ID 437971, 18 pages. [DOI:10.1155/2014/437971] [PMID] [PMCID]
  21. Veruttipong D, Soliman AS, Gilbert SF, Blachley TS, Hablas A, Ramadan M. et al. Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol. 2012;18(30):3997-4003. [PMID] [DOI:10.3748/wjg.v18.i30.3997] [PMCID]
  22. Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K. et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int. J. Cancer.2009;125: 926-931. [DOI:10.1002/ijc.24453] [PMID]
  23. Miyazaki S., Kikuchi H., Iino I., Uehara T., Setoguchi T., Fujita T. et al. Anti‐VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int. J. Cancer 2014;135: 295-307. [DOI:10.1002/ijc.28686] [PMID]
  24. Yuan Q, Zhan L, Zhang LL, Wang Q, Liu J, Jiang ZY et al. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein. Can J Physiol Pharmacol. 2016;94(9):929-35. [DOI:10.1139/cjpp-2015-0530] [PMID]
  25. Chen B, Zeng X, He Y, Wang X, Liang Z, Liu J et al. STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget. 2016 Nov 1;7(44):71400-71416. [PMID] [PMCID] [DOI:10.18632/oncotarget.12147]
  26. Chen X, Liu Q, Huang W, Cai C, Xia W, Peng Y et al. Stanniocalcin-2 contributes to mesenchymal stromal cells attenuating murine contact hypersensitivity mainly via reducing CD8+ Tc1 cells. Cell Death Dis 2018; 9(5): 548. [PMCID] [DOI:10.1038/s41419-018-0614-x] [PMID]
  27. Li Q, Zhou X, Fang Z, Pan Z. Effect of STC2 gene silencing on colorectal cancer cells. Mol Med Rep 2019; 20: 977-984. [PMID] [PMCID] [DOI:10.3892/mmr.2019.10332]
  28. Kim MS, Park EJ, Kang J, Min BS, Lee KY, Kim NK et al. Prognostic factors predicting survival in incurable stage IV colorectal cancer patients who underwent palliative primary tumor resection. Retrospective cohort study. Int J Surg. 2018; 49: 10-15. [DOI:10.1016/j.ijsu.2017.11.038] [PMID]
  29. Dai W, Mo S, Xiang W, Han L, Li Q, Wang R et al. The Critical Role of Tumor Size in Predicting Prognosis for T1 Colon Cancer. Oncologist. 2020;25(3):244-251. [PMCID] [DOI:10.1634/theoncologist.2019-0469]
  30. Kim HJ, Choi GS. Clinical Implications of Lymph Node Metastasis in Colorectal Cancer: Current Status and Future Perspectives. Ann Coloproctol. 2019;35(3):109-117. [DOI:10.3393/ac.2019.06.12] [PMID] [PMCID]
  31. Cienfuegos JA, Martínez P, Baixauli J, Beorlegui C, Rosenstone S, Sola JJ et al. Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer. Ann Surg Oncol. 2017;24(4):1077-1084. [DOI:10.1245/s10434-016-5561-0] [PMID]
  32. Sun Q, Liu T, Liu P, Luo J, Zhang N, Lu K et al. Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery. J Cancer. 2019; 21;10(10):2243-2249. [DOI:10.7150/jca.31473] [PMID] [PMCID]
  33. Miyazaki S, Kikuchi H, Iino I, Uehara T, Setoguchi T, Fujita T et al. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer. 2014;135(2):295-307. [DOI:10.1002/ijc.28686] [PMID]
  34. Li Q, Zhou X, Fang Z, Pan Z. Effect of STC2 gene silencing on colorectal cancer cells. Molecular medicine reports. 2019;20(2):977-84. [PMID] [PMCID] [DOI:10.3892/mmr.2019.10332]